Isolated Elevation of Alkaline Phosphatase Level Associated with Rosiglitazone
Authors: David M. Hachey
Journal: Annals of Internal Medicine (2000)

Letters7 November 2000Isolated Elevation of Alkaline Phosphatase Level Associated with RosiglitazoneDavid M. Hachey, PharmD, Michael P. O'Neil, MD, and Rex W. Force, PharmD, BCPSDavid M. Hachey, PharmDIdaho State University; Pocatello, ID 83209-8357 (Hachey, O'Neil, Force), Michael P. O'Neil, MDIdaho State University; Pocatello, ID 83209-8357 (Hachey, O'Neil, Force), and Rex W. Force, PharmD, BCPSIdaho State University; Pocatello, ID 83209-8357 (Hachey, O'Neil, Force)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-9-200011070-00035 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:A 47-year-old woman with a history of type 2 diabetes mellitus, hypertension, herpes zoster, depression, and diabetic gastroparesis presented for follow-up and routine laboratory evaluation. Her physical examination was benign, and her hepatic function panel was normal except for a serum alkaline phosphatase level elevated five times the upper limit of normal (10.93 µkat/L). She had no history of liver disease, but approximately 1 year before presentation she had slightly elevated aminotransferase levels (alanine aminotransferase, 1283 nkat/L; aspartate aminotransferase, 0.73 µkat/L).Her medication regimen included metformin, 850 mg three times daily; sertraline, 50 mg/d; losartan, 50 mg ...References1. Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure [Letter]. Ann Intern Med. 2000;132:164. LinkGoogle Scholar2. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med. 2000;132:121-4. LinkGoogle Scholar3. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-21. LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Idaho State University; Pocatello, ID 83209-8357 (Hachey, O'Neil, Force) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHepatic Failure in a Patient Taking Rosiglitazone Lisa M. Forman , David A. Simmons , and Robert H. Diamond Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report Jameela Al-Salman , Heider Arjomand , David G. Kemp , and Manoj Mittal Rosiglitazone and Hepatic Failure Jeffrey Freid , Daniel Everitt , and Jerome Boscia Metrics Cited ByEffects of rosiglitazone on growth and skeletal muscle glucose metabolism of GIFT tilapia based on PI3K/Akt signaling pathwayRosiglitazone promotes glucose metabolism of GIFT tilapia based on the PI3K/Akt signaling pathwayDrugs and ToxinsThiazolidinedionesHepatic injury due to drugs, herbal compounds, chemicals and toxinsImportant Elements for the Diagnosis of Drug-Induced Liver InjuryLiver Disease Caused by DrugsINSULINS AND OTHER HYPOGLYCEMIC DRUGSThiazolidinedionesHepatic Injury in a Patient Taking RosiglitazoneThe "Glitazones": Rosiglitazone and PioglitazoneEditor's MailboxInsulin, glucagon, and hypoglycemic drugsRosiglitazoneA Review of Rosiglitazone in Type 2 Diabetes MellitusDrug-induced liver disease 7 November 2000Volume 133, Issue 9Page: 752KeywordsLiverLiver diseasesMedical risk factorsPhosphatasesPhosphatesResearch laboratoriesRisk managementSerum glutamic oxaloacetic transaminaseToxicityType 2 diabetes ePublished: 7 November 2000 Issue Published: 7 November 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...